# Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma

> **NCT01727778** · PHASE1 · COMPLETED · sponsor: **Patrys Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Drug Safety

## Interventions

- **BIOLOGICAL:** Anti-GRP78 monoclonal IgM antibody PAT-SM6

## Key facts

- **NCT ID:** NCT01727778
- **Lead sponsor:** Patrys Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2015-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01727778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01727778, "Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01727778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*